- Home
- AUPH vs PDX Comparison
AUPH vs PDX Comparison
Compare AUPH & PDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- PDX
- Stock Information
- Founded
- AUPH 1993
- PDX 2019
- Country
- AUPH Canada
- PDX NY
- Employees
- AUPH N/A
- PDX N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- PDX Finance/Investors Services
- Sector
- AUPH Health Care
- PDX Finance
- Exchange
- AUPH Nasdaq
- PDX Nasdaq
- Market Cap
- AUPH 1.4B
- PDX 1.1B
- IPO Year
- AUPH 1999
- PDX N/A
- Fundamental
- Price
- AUPH $12.81
- PDX $24.58
- Analyst Decision
- AUPH Strong Buy
- PDX
- Analyst Count
- AUPH 3
- PDX 0
- Target Price
- AUPH $12.00
- PDX N/A
- AVG Volume (30 Days)
- AUPH 1.6M
- PDX N/A
- Earning Date
- AUPH 11-06-2025
- PDX 01-01-0001
- Dividend Yield
- AUPH N/A
- PDX 4.95%
- EPS Growth
- AUPH N/A
- PDX N/A
- EPS
- AUPH 0.42
- PDX N/A
- Revenue
- AUPH $260,111,000.00
- PDX N/A
- Revenue This Year
- AUPH $16.92
- PDX N/A
- Revenue Next Year
- AUPH $14.43
- PDX N/A
- P/E Ratio
- AUPH $30.61
- PDX N/A
- Revenue Growth
- AUPH 25.59
- PDX N/A
- 52 Week Low
- AUPH $6.43
- PDX $13.52
- 52 Week High
- AUPH $12.90
- PDX $21.05
- Technical
- Relative Strength Index (RSI)
- AUPH 68.86
- PDX 50.53
- Support Level
- AUPH $12.06
- PDX $24.60
- Resistance Level
- AUPH $12.82
- PDX $25.00
- Average True Range (ATR)
- AUPH 0.37
- PDX 0.29
- MACD
- AUPH -0.04
- PDX 0.01
- Stochastic Oscillator
- AUPH 93.23
- PDX 47.50
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About PDX PIMCO Dynamic Income Strategy Fund of Beneficial Interest
PIMCO Dynamic Income Strategy Fund is a non-diversified, limited-term, closed-end management investment company. It seeks current income as a primary objective and capital appreciation as a secondary objective. The fund makes investments using a dynamic asset allocation plan among multiple sectors in the public and private credit markets globally, including corporate debt, mortgage-related and other asset-backed instruments, government and sovereign debt, taxable municipal bonds, and other fixed, variable, and floating-rate income-producing securities of U.S. and foreign issuers, including emerging market issuers and real estate-related investments.